Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total transaction of $362,246.40. Following the sale, the executive vice president now owns 12,881 shares of the company's stock, valued at $3,240,344.36. This trade represents a 10.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Kevin Joseph Fitzgerald also recently made the following trade(s):
- On Friday, February 14th, Kevin Joseph Fitzgerald sold 663 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $255.21, for a total transaction of $169,204.23.
Alnylam Pharmaceuticals Trading Down 0.2 %
ALNY stock traded down $0.41 during midday trading on Friday, hitting $250.59. The stock had a trading volume of 649,260 shares, compared to its average volume of 693,578. The firm has a market cap of $32.44 billion, a P/E ratio of -115.48 and a beta of 0.35. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The business has a fifty day moving average price of $254.04 and a two-hundred day moving average price of $263.12.
Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Alnylam Pharmaceuticals
Institutional investors have recently made changes to their positions in the stock. Huntington National Bank raised its holdings in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 45 shares during the period. Hollencrest Capital Management acquired a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth about $29,000. Larson Financial Group LLC raised its holdings in shares of Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 73 shares during the last quarter. R Squared Ltd acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $33,000. Finally, Colonial Trust Co SC acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $35,000. Institutional investors and hedge funds own 92.97% of the company's stock.
Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on the stock. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, January 9th. Piper Sandler reissued an "overweight" rating and issued a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Royal Bank of Canada reissued an "outperform" rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 11th. HC Wainwright reissued a "buy" rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. Finally, Canaccord Genuity Group lifted their price objective on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a "buy" rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $299.48.
Check Out Our Latest Research Report on Alnylam Pharmaceuticals
About Alnylam Pharmaceuticals
(
Get Free Report)
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Recommended Stories
Before you consider Alnylam Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.
While Alnylam Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
